$1.670
+0.031 (+1.83%)收盘时
BTMD 资讯
BTMD 事件
Sees FY26 Adjusted EBITDA Above $25M
Sees FY26 adjusted EBITDA above $25M
Biote Reports Q2 Revenue of $44.2M, Below Expectations
Reports Q2 revenue $44.2M, consensus $46.08M. "Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth," said Bob Peterson, Biote's interim Chief Executive Officer. "While not yet evident in our financial results, these foundational improvements have strengthened the core of our business and enhanced our resiliency, which we expect will drive improved financial performance in the second half."
Biote Appoints Komal Bajaj as Chief Medical Officer
Biote announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj joins Biote following senior leadership roles within NYC Health + Hospitals, where she most recently served as Chief Quality Officer for Jacobi Hospital and North Central Bronx Hospital.
Biote CFO Bob Peterson Named Interim CEO
Biote announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company's Board of Directors. In addition, Marc Beer, Biote's Chairman, will assume the role of Executive Chairman.
Biote Sees FY26 Revenue Over $190M
Biote sees FY26 revenue over $190M, consensus $191.7M
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。